International Biotechnology - IBT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 947.90
▲ +7.9 (0.84%)

This chart shows the closing price for IBT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New International Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IBT

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for International Biotechnology in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 947.90.

This chart shows the closing price for IBT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in International Biotechnology. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2021BarclaysReiterated RatingOverweightGBX 260
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2025
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/6/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2025

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
International Biotechnology logo
The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services. While the Company’s portfolio is held as one pool of assets, for operational purposes there is a quoted portfolio and an unquoted portfolio. The portfolio is diversified by geography, industry sub-sector and investment size with no single investment in a company normally accounting for more than 15% of the portfolio at the time of investment. The portfolio is split between large, mid and small-capitalisation companies, primarily quoted on stock exchanges in North America, where the most established and commercial biotech and other life sciences companies and companies operating in related sectors are based, though investments will also be made in Europe, Asia and Australia. Investments may also be made into unquoted companies and into funds not quoted on a stock exchange, including venture capital funds. This may include funds managed by the Investment Manager and/or members of its group. The primary purpose of investment in unquoted funds will be to gain exposure to unquoted companies. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. Forward or derivative transactions are not used by the Company. The Company may borrow from time to time to exploit specific investment opportunities, rather than to apply long-term structural gearing to the Company’s portfolio of investments.
Read More

Today's Range

Now: GBX 947.90
Low: 924
High: 949.90

50 Day Range

MA: GBX 850.72
Low: 738
High: 964

52 Week Range

Now: GBX 947.90
Low: 480
High: 976

Volume

62,370 shs

Average Volume

105,476 shs

Market Capitalization

£302.41 million

P/E Ratio

N/A

Dividend Yield

3.43%

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of International Biotechnology?

The following Wall Street sell-side analysts have issued stock ratings on International Biotechnology in the last twelve months:
View the latest analyst ratings for IBT.

What is the current price target for International Biotechnology?

0 Wall Street analysts have set twelve-month price targets for International Biotechnology in the last year. has the lowest price target set, forecasting a price of £100,000 for International Biotechnology in the next year.
View the latest price targets for IBT.

What is the current consensus analyst rating for International Biotechnology?

International Biotechnology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IBT.

What other companies compete with International Biotechnology?

How do I contact International Biotechnology's investor relations team?

International Biotechnology's physical mailing address is 10 Harewood Avenue, LONDON, NW1 6AA, United Kingdom. The company's listed phone number is 44 20 7421 7070. The official website for International Biotechnology is www.ibtplc.com. Learn More about contacing International Biotechnology investor relations.